The study to investigate effects of ezetimibe on the changes in plasma incretins

The study to investigate effects of ezetimibe on the changes in plasma incretins - The study to investigate effects of ezetimibe on the changes in plasma incretins

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007225

Enrollment

Registered

2012-02-06

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

ezetimibe 10 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: LDL cholesterol >= 140 mg/dl with and without statin use

Exclusion criteria

Exclusion criteria: 1. hypersensitivity to ezetimibe 2. patients with insulin, arufa-glucosidase inhibitor, biguanide or thiazolidinedione 3. patients with severe hepatic disease 4. patients with severe renal dysfunction 5. secondary hypercholesterolemia 6. familiar hypercholesterolemia 7. patients who are judged as inappropriate for this study by physicians

Design outcomes

Primary

Measure	Time frame
The effects of ezetimibe on the changes in plasma incretins during meal tolerance test	—

Countries

Japan

Contacts

Public ContactTakuma Narita

Akita University Graduate School of Medicine Department of Endocrinology, Diabetes and Geriatric Medicine

narita@med.akita-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026